Drugs / QRX-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07161843 | Jun → Dec 2026 expected | acute kidney tubular necrosis | Ebima Clifford Okundaye | Not yet recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06948292 Comparator | Mar 2023 → Aug 2024 | diabetic kidney disease, hypertensive nephropathy | Ebima Clifford Okundaye | Completed | No outcome recorded |
| Phase 2/3 | NCT06866236 Comparator | Oct 2025 → Oct 2026 expected | acute kidney injury, chronic kidney disease | Ebima Clifford Okundaye | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QRX-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06948292 ↗ |
| Route | Oral | “QRX-3 - two capsules orally twice daily” NCT06866236 ↗ |